FDA’s $6.4 Billion Plan for Quick Reviews Moves to Senate

A $6.4 billion effort to speed U.S. reviews of new drugs and medical devices is a step closer to law as the agreements Mylan Inc., Pfizer Inc. and other companies struck with regulators wind through Congress.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.